Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs 10X Genomics Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.93 (market cap $3.56B), while 10X Genomics Inc trades at $82.4 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.8× GraniteShares 2x Long NVDA Daily ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and 10X Genomics Inc for 92 Days on average.
| NVDL | TXG | |
|---|---|---|
Market Cap | $3.56B | $10.07B |
Volume | 9,740,643 | 5,657,286 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $97.74 |
52-Week Low | $21.76 | $11.48 |
Typical Hold Time | 15 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $37.335, down 5.65% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. Recent news highlights Nvidia's continued AI leadership and earnings beats, driving leveraged ETF interest. The ETF aims to deliver 2x daily returns of Nvidia stock, with technical analysis showing support at $36 and resistance at $38-39 levels.
The outlook remains tied to Nvidia's AI dominance and earnings performance. Investment opportunity exists through leveraged exposure to Nvidia's growth trajectory, though risks include daily reset leverage decay and Nvidia's high valuation. Recent SpaceX earnings have reshuffled AI chip trades, creating volatility. The ETF's performance depends on Nvidia maintaining its AI market leadership and execution.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
